{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T15:11:21Z","timestamp":1784819481626,"version":"3.55.0"},"reference-count":150,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2020,5,13]],"date-time":"2020-05-13T00:00:00Z","timestamp":1589328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,5,13]],"date-time":"2020-05-13T00:00:00Z","timestamp":1589328000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Res Cardiol"],"published-print":{"date-parts":[[2020,10]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The acute and long-lasting side effects of modern multimodal tumour therapy significantly impair quality of life and survival of patients afflicted with malignancies. The key components of this therapy include radiotherapy, conventional chemotherapy, immunotherapy and targeted therapies. In addition to established tumour therapy strategies, up to 30 new therapies are approved each year with only incompletely characterised side effects. This consensus paper discusses the risk factors that contribute to the development of a potentially adverse reaction to tumour therapy and, in addition, defines specific side effect profiles for different treatment groups. The focus is on novel therapeutics and recommendations for the surveillance and treatment of specific patient groups.<\/jats:p>","DOI":"10.1007\/s00392-020-01636-7","type":"journal-article","created":{"date-parts":[[2020,5,13]],"date-time":"2020-05-13T09:19:30Z","timestamp":1589361570000},"page":"1197-1222","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":91,"title":["Onco-Cardiology: Consensus Paper of the German Cardiac Society, the German Society for Pediatric Cardiology and Congenital Heart Defects and the German Society for Hematology and Medical Oncology"],"prefix":"10.1007","volume":"109","author":[{"name":"Committee for Clinical Cardiovascular Medicine of the German Cardiac Society","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tienush","family":"Rassaf","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias","family":"Totzeck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johannes","family":"Backs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carsten","family":"Bokemeyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Hallek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Denise","family":"Hilfiker-Kleiner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Hochhaus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diana","family":"L\u00fcftner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oliver J.","family":"M\u00fcller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulrich","family":"Neudorf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roman","family":"Pfister","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephan","family":"von Haehling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorenz H.","family":"Lehmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johann","family":"Bauersachs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,5,13]]},"reference":[{"key":"1636_CR1","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.clcc.2018.10.006","volume":"18","author":"O Abdel-Rahman","year":"2019","unstructured":"Abdel-Rahman O (2019) 5-Fluorouracil-related cardiotoxicity; findings from five randomized studies of 5-fluorouracil-based regimens in metastatic colorectal cancer. Clin Colorectal Cancer 18:58\u201363","journal-title":"Clin Colorectal Cancer"},{"key":"1636_CR2","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1093\/eurheartj\/ehq456","volume":"32","author":"S Agewall","year":"2011","unstructured":"Agewall S, Giannitsis E, Jernberg T et al (2011) Troponin elevation in coronary vs. non-coronary disease. Eur Heart J 32:404\u2013411","journal-title":"Eur Heart J"},{"key":"1636_CR3","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1161\/CIRCULATIONAHA.118.035898","volume":"138","author":"C Anquetil","year":"2018","unstructured":"Anquetil C, Salem JE, Lebrun-Vignes B et al (2018) Immune checkpoint inhibitor-associated myositis. Circulation 138:743\u2013745","journal-title":"Circulation"},{"key":"1636_CR4","doi-asserted-by":"crossref","first-page":"e123","DOI":"10.1016\/S1470-2045(14)70409-7","volume":"16","author":"SH Armenian","year":"2015","unstructured":"Armenian SH, Hudson MM, Mulder RL et al (2015) Recommendations for cardiomyopathy surveillance for survivors of childhood cancer: a report from the International Late Effects of Childhood Cancer Guideline Harmonization Group. Lancet Oncol 16:e123\u2013136","journal-title":"Lancet Oncol"},{"key":"1636_CR5","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1200\/JCO.2016.70.5400","volume":"35","author":"SH Armenian","year":"2017","unstructured":"Armenian SH, Lacchetti C, Barac A et al (2017) Prevention and monitoring of cardiac dysfunction in survivors of adult cancers: American society of clinical oncology clinical practice guideline. J Clin Oncol 35:893\u2013911","journal-title":"J Clin Oncol"},{"key":"1636_CR6","doi-asserted-by":"crossref","first-page":"5537","DOI":"10.1200\/JCO.2008.17.7428","volume":"26","author":"SH Armenian","year":"2008","unstructured":"Armenian SH, Sun CL, Francisco L et al (2008) Late congestive heart failure after hematopoietic cell transplantation. J Clin Oncol 26:5537\u20135543","journal-title":"J Clin Oncol"},{"key":"1636_CR7","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1200\/JCO.2015.64.0409","volume":"34","author":"SH Armenian","year":"2016","unstructured":"Armenian SH, Xu L, Ky B et al (2016) Cardiovascular disease among survivors of adult-onset cancer: a community-based retrospective cohort study. J Clin Oncol 34:1122\u20131130","journal-title":"J Clin Oncol"},{"key":"1636_CR8","doi-asserted-by":"crossref","first-page":"2511","DOI":"10.1016\/j.jacc.2015.04.013","volume":"65","author":"GT Armstrong","year":"2015","unstructured":"Armstrong GT, Joshi VM, Ness KK et al (2015) Comprehensive echocardiographic detection of treatment-related cardiac dysfunction in adult survivors of childhood cancer: results from the St. Jude lifetime cohort study. J Am Coll Cardiol 65:2511\u20132522","journal-title":"J Am Coll Cardiol"},{"key":"1636_CR9","doi-asserted-by":"crossref","first-page":"2976","DOI":"10.1016\/j.jacc.2019.03.500","volume":"73","author":"KM Atkins","year":"2019","unstructured":"Atkins KM, Rawal B, Chaunzwa TL et al (2019) Cardiac radiation dose, cardiac disease, and mortality in patients with lung cancer. J Am Coll Cardiol 73:2976","journal-title":"J Am Coll Cardiol"},{"key":"1636_CR10","doi-asserted-by":"crossref","first-page":"2869","DOI":"10.1016\/j.jacc.2019.04.006","volume":"73","author":"A Barac","year":"2019","unstructured":"Barac A, Blaes A, Lynce F (2019) Lessons from primary cardiac prevention trials during trastuzumab therapy: end of one size fits all. J Am Coll Cardiol 73:2869\u20132871","journal-title":"J Am Coll Cardiol"},{"key":"1636_CR11","doi-asserted-by":"crossref","first-page":"2048","DOI":"10.1158\/1055-9965.EPI-11-0659","volume":"20","author":"S Bhatia","year":"2011","unstructured":"Bhatia S (2011) Role of genetic susceptibility in development of treatment-related adverse outcomes in cancer survivors. Cancer Epidemiol Biomarkers Prev 20:2048\u20132067","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"1636_CR12","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1093\/jnci\/djs317","volume":"104","author":"EJ Bowles","year":"2012","unstructured":"Bowles EJ, Wellman R, Feigelson HS et al (2012) Risk of heart failure in breast cancer patients after anthracycline and trastuzumab treatment: a retrospective cohort study. J Natl Cancer Inst 104:1293\u20131305","journal-title":"J Natl Cancer Inst"},{"key":"1636_CR13","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1200\/JCO.2017.77.6385","volume":"36","author":"JR Brahmer","year":"2018","unstructured":"Brahmer JR, Lacchetti C, Schneider BJ et al (2018) Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American society of clinical oncology clinical practice guideline. J Clin Oncol 36:1714\u20131768","journal-title":"J Clin Oncol"},{"key":"1636_CR14","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1007\/s00108-018-0491-5","volume":"60","author":"S Braumann","year":"2019","unstructured":"Braumann S, Peitsch WK, Pfister R et al (2019) Angina pectoris in a 47-year-old athletic man with psoriasis vulgaris. Internist (Berl) 60:86\u201389","journal-title":"Internist (Berl)"},{"key":"1636_CR15","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1038\/nm.4087","volume":"22","author":"PW Burridge","year":"2016","unstructured":"Burridge PW, Li YF, Matsa E et al (2016) Human induced pluripotent stem cell-derived cardiomyocytes recapitulate the predilection of breast cancer patients to doxorubicin-induced cardiotoxicity. Nat Med 22:547\u2013556","journal-title":"Nat Med"},{"issue":"2636\u20132648","key":"1636_CR16","first-page":"2648a","volume":"34","author":"AL Caforio","year":"2013","unstructured":"Caforio AL, Pankuweit S, Arbustini E et al (2648d) Current state of knowledge on aetiology, diagnosis, management, and therapy of myocarditis: a position statement of the European Society of Cardiology Working Group on myocardial and pericardial diseases. Eur Heart J 34(2636\u20132648):2648a\u20132648d","journal-title":"Eur Heart J"},{"key":"1636_CR17","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.cjca.2018.11.028","volume":"35","author":"O Calvillo-Arguelles","year":"2019","unstructured":"Calvillo-Arguelles O, Abdel-Qadir H, Michalowska M et al (2019) Cardioprotective effect of statins in patients with HER2-positive breast cancer receiving trastuzumab therapy. Can J Cardiol 35:153\u2013159","journal-title":"Can J Cardiol"},{"key":"1636_CR18","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.ijcard.2019.04.051","volume":"288","author":"G Caocci","year":"2019","unstructured":"Caocci G, Mulas O, Bonifacio M et al (2019) Recurrent arterial occlusive events in patients with chronic myeloid leukemia treated with second- and third-generation tyrosine kinase inhibitors and role of secondary prevention. Int J Cardiol 288:124\u2013127","journal-title":"Int J Cardiol"},{"key":"1636_CR19","doi-asserted-by":"crossref","first-page":"1981","DOI":"10.1161\/CIRCULATIONAHA.114.013777","volume":"131","author":"D Cardinale","year":"2015","unstructured":"Cardinale D, Colombo A, Bacchiani G et al (2015) Early detection of anthracycline cardiotoxicity and improvement with heart failure therapy. Circulation 131:1981\u20131988","journal-title":"Circulation"},{"key":"1636_CR20","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1007\/s40262-019-00748-2","volume":"58","author":"M Centanni","year":"2019","unstructured":"Centanni M, Moes D, Troconiz IF et al (2019) Clinical pharmacokinetics and pharmacodynamics of immune checkpoint inhibitors. Clin Pharmacokinet 58:835\u2013857","journal-title":"Clin Pharmacokinet"},{"key":"1636_CR21","doi-asserted-by":"crossref","first-page":"2552","DOI":"10.1016\/j.jacc.2017.09.1095","volume":"70","author":"HM Chang","year":"2017","unstructured":"Chang HM, Okwuosa TM, Scarabelli T et al (2017) Cardiovascular complications of cancer therapy: best practices in diagnosis, prevention, and management: Part 2. J Am Coll Cardiol 70:2552\u20132565","journal-title":"J Am Coll Cardiol"},{"key":"1636_CR22","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1182\/bloodadvances.2017015545","volume":"2","author":"A Chari","year":"2018","unstructured":"Chari A, Stewart AK, Russell SD et al (2018) Analysis of carfilzomib cardiovascular safety profile across relapsed and\/or refractory multiple myeloma clinical trials. Blood Adv 2:1633\u20131644","journal-title":"Blood Adv"},{"issue":"3","key":"1636_CR23","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1093\/jnci\/djz108","volume":"112","author":"Y Chen","year":"2020","unstructured":"Chen Y, Chow EJ, Oeffinger KC et al (2020) Traditional cardiovascular risk factors and individual prediction of cardiovascular events in childhood cancer survivors. J Natl Cancer Inst 112(3):256\u2013265. https:\/\/doi.org\/10.1093\/jnci\/djz108","journal-title":"J Natl Cancer Inst"},{"key":"1636_CR24","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1200\/JCO.2013.52.6582","volume":"32","author":"EJ Chow","year":"2014","unstructured":"Chow EJ, Baker KS, Lee SJ et al (2014) Influence of conventional cardiovascular risk factors and lifestyle characteristics on cardiovascular disease after hematopoietic cell transplantation. J Clin Oncol 32:191\u2013198","journal-title":"J Clin Oncol"},{"key":"1636_CR25","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1200\/JCO.2017.74.8673","volume":"36","author":"EJ Chow","year":"2018","unstructured":"Chow EJ, Chen Y, Hudson MM et al (2018) Prediction of ischemic heart disease and stroke in survivors of childhood cancer. J Clin Oncol 36:44\u201352","journal-title":"J Clin Oncol"},{"key":"1636_CR26","doi-asserted-by":"crossref","first-page":"1946","DOI":"10.1200\/JCO.19.00231","volume":"37","author":"RF Cornell","year":"2019","unstructured":"Cornell RF, Ky B, Weiss BM et al (2019) Prospective study of cardiac events during proteasome inhibitor therapy for relapsed multiple myeloma. J Clin Oncol 37:1946\u20131955","journal-title":"J Clin Oncol"},{"key":"1636_CR27","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1056\/NEJMoa1306494","volume":"369","author":"JE Cortes","year":"2013","unstructured":"Cortes JE, Kim DW, Pinilla-Ibarz J et al (2013) A phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemias. N Engl J Med 369:1783\u20131796","journal-title":"N Engl J Med"},{"issue":"Suppl 1","key":"1636_CR28","doi-asserted-by":"crossref","first-page":"S77","DOI":"10.1016\/j.ihj.2016.01.022","volume":"68","author":"RM Cubbon","year":"2016","unstructured":"Cubbon RM, Lyon AR (2016) Cardio-oncology: concepts and practice. Indian Heart J 68(Suppl 1):S77\u201385","journal-title":"Indian Heart J"},{"key":"1636_CR29","doi-asserted-by":"crossref","first-page":"504","DOI":"10.4330\/wjc.v8.i9.504","volume":"8","author":"JR Cuomo","year":"2016","unstructured":"Cuomo JR, Sharma GK, Conger PD et al (2016) Novel concepts in radiation-induced cardiovascular disease. World J Cardiol 8:504\u2013519","journal-title":"World J Cardiol"},{"issue":"4","key":"1636_CR30","doi-asserted-by":"publisher","first-page":"djv008","DOI":"10.1093\/jnci\/djv008","volume":"107","author":"DJ Cutter","year":"2015","unstructured":"Cutter DJ, Schaapveld M, Darby SC et al (2015) Risk of valvular heart disease after treatment for Hodgkin lymphoma. J Natl Cancer Inst 107(4):djv008. https:\/\/doi.org\/10.1093\/jnci\/djv008","journal-title":"J Natl Cancer Inst"},{"key":"1636_CR31","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1111\/ejh.12677","volume":"97","author":"S Danhof","year":"2016","unstructured":"Danhof S, Schreder M, Rasche L et al (2016) 'Real-life' experience of preapproval carfilzomib-based therapy in myeloma\u2014analysis of cardiac toxicity and predisposing factors. Eur J Haematol 97:25\u201332","journal-title":"Eur J Haematol"},{"key":"1636_CR32","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1056\/NEJMoa1209825","volume":"368","author":"SC Darby","year":"2013","unstructured":"Darby SC, Ewertz M, Mcgale P et al (2013) Risk of ischemic heart disease in women after radiotherapy for breast cancer. N Engl J Med 368:987\u2013998","journal-title":"N Engl J Med"},{"key":"1636_CR33","doi-asserted-by":"crossref","first-page":"2517","DOI":"10.1016\/j.ejca.2015.08.011","volume":"51","author":"E De Azambuja","year":"2015","unstructured":"De Azambuja E, Ameye L, Diaz M et al (2015) Cardiac assessment of early breast cancer patients 18 years after treatment with cyclophosphamide-, methotrexate-, fluorouracil- or epirubicin-based chemotherapy. Eur J Cancer 51:2517\u20132524","journal-title":"Eur J Cancer"},{"key":"1636_CR34","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1016\/j.jacc.2019.07.006","volume":"74","author":"MY Desai","year":"2019","unstructured":"Desai MY, Windecker S, Lancellotti P et al (2019) Prevention, diagnosis, and management of radiation-associated cardiac disease: JACC scientific expert panel. J Am Coll Cardiol 74:905\u2013927","journal-title":"J Am Coll Cardiol"},{"key":"1636_CR35","doi-asserted-by":"crossref","first-page":"2147","DOI":"10.1038\/leu.2009.147","volume":"23","author":"MA Dimopoulos","year":"2009","unstructured":"Dimopoulos MA, Chen C, Spencer A et al (2009) Long-term follow-up on overall survival from the MM-009 and MM-010 phase III trials of lenalidomide plus dexamethasone in patients with relapsed or refractory multiple myeloma. Leukemia 23:2147\u20132152","journal-title":"Leukemia"},{"key":"1636_CR36","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/S1470-2045(15)00464-7","volume":"17","author":"MA Dimopoulos","year":"2016","unstructured":"Dimopoulos MA, Moreau P, Palumbo A et al (2016) Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study. Lancet Oncol 17:27\u201338","journal-title":"Lancet Oncol"},{"key":"1636_CR37","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1136\/heartjnl-2018-313726","volume":"104","author":"SJH Dobbin","year":"2018","unstructured":"Dobbin SJH, Cameron AC, Petrie MC et al (2018) Toxicity of cancer therapy: what the cardiologist needs to know about angiogenesis inhibitors. Heart 104:1995\u20132002","journal-title":"Heart"},{"key":"1636_CR38","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.taap.2013.04.027","volume":"272","author":"KR Doherty","year":"2013","unstructured":"Doherty KR, Wappel RL, Talbert DR et al (2013) Multi-parameter in vitro toxicity testing of crizotinib, sunitinib, erlotinib, and nilotinib in human cardiomyocytes. Toxicol Appl Pharmacol 272:245\u2013255","journal-title":"Toxicol Appl Pharmacol"},{"key":"1636_CR39","doi-asserted-by":"crossref","first-page":"2085","DOI":"10.1161\/CIRCULATIONAHA.117.030571","volume":"136","author":"M Escudier","year":"2017","unstructured":"Escudier M, Cautela J, Malissen N et al (2017) Clinical features, management, and outcomes of immune checkpoint inhibitor-related cardiotoxicity. Circulation 136:2085\u20132087","journal-title":"Circulation"},{"key":"1636_CR40","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1016\/j.amjcard.2003.12.061","volume":"93","author":"IE Fahdi","year":"2004","unstructured":"Fahdi IE, Gaddam V, Saucedo JF et al (2004) Bradycardia during therapy for multiple myeloma with thalidomide. Am J Cardiol 93:1052\u20131055","journal-title":"Am J Cardiol"},{"key":"1636_CR41","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/j.repc.2016.04.006","volume":"35","author":"M Fiuza","year":"2016","unstructured":"Fiuza M, Ribeiro L, Magalhaes A et al (2016) Organization and implementation of a cardio-oncology program. Rev Port Cardiol 35:485\u2013494","journal-title":"Rev Port Cardiol"},{"key":"1636_CR42","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1111\/bjh.14970","volume":"180","author":"MG Fradley","year":"2018","unstructured":"Fradley MG, Groarke JD, Laubach J et al (2018) Recurrent cardiotoxicity potentiated by the interaction of proteasome inhibitor and immunomodulatory therapy for the treatment of multiple myeloma. Br J Haematol 180:271\u2013275","journal-title":"Br J Haematol"},{"key":"1636_CR43","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1016\/j.jacep.2018.06.004","volume":"4","author":"S Ganatra","year":"2018","unstructured":"Ganatra S, Sharma A, Shah S et al (2018) Ibrutinib-associated atrial fibrillation. JACC Clin Electrophysiol 4:1491\u20131500","journal-title":"JACC Clin Electrophysiol"},{"key":"1636_CR44","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1158\/1940-6207.CAPR-13-0424","volume":"7","author":"S Gandini","year":"2014","unstructured":"Gandini S, Puntoni M, Heckman-Stoddard BM et al (2014) Metformin and cancer risk and mortality: a systematic review and meta-analysis taking into account biases and confounders. Cancer Prev Res (Phila) 7:867\u2013885","journal-title":"Cancer Prev Res (Phila)"},{"key":"1636_CR45","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1038\/bjc.2014.564","volume":"112","author":"P Ghatalia","year":"2015","unstructured":"Ghatalia P, Je Y, Kaymakcalan MD et al (2015) QTc interval prolongation with vascular endothelial growth factor receptor tyrosine kinase inhibitors. Br J Cancer 112:296\u2013305","journal-title":"Br J Cancer"},{"key":"1636_CR46","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.critrevonc.2014.12.008","volume":"94","author":"P Ghatalia","year":"2015","unstructured":"Ghatalia P, Morgan CJ, Je Y et al (2015) Congestive heart failure with vascular endothelial growth factor receptor tyrosine kinase inhibitors. Crit Rev Oncol Hematol 94:228\u2013237","journal-title":"Crit Rev Oncol Hematol"},{"key":"1636_CR47","doi-asserted-by":"crossref","first-page":"1674","DOI":"10.2337\/dc10-0666","volume":"33","author":"E Giovannucci","year":"2010","unstructured":"Giovannucci E, Harlan DM, Archer MC et al (2010) Diabetes and cancer: a consensus report. Diabetes Care 33:1674\u20131685","journal-title":"Diabetes Care"},{"key":"1636_CR48","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1016\/j.jchf.2019.04.014","volume":"7","author":"S Goel","year":"2019","unstructured":"Goel S, Liu J, Guo H et al (2019) Decline in left ventricular ejection fraction following anthracyclines predicts trastuzumab cardiotoxicity. JACC Heart Fail 7:795\u2013804","journal-title":"JACC Heart Fail"},{"key":"1636_CR49","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1093\/eurheartj\/eht114","volume":"35","author":"JD Groarke","year":"2014","unstructured":"Groarke JD, Nguyen PL, Nohria A et al (2014) Cardiovascular complications of radiation therapy for thoracic malignancies: the role for non-invasive imaging for detection of cardiovascular disease. Eur Heart J 35:612\u2013623","journal-title":"Eur Heart J"},{"key":"1636_CR50","doi-asserted-by":"crossref","first-page":"2859","DOI":"10.1016\/j.jacc.2019.03.495","volume":"73","author":"M Guglin","year":"2019","unstructured":"Guglin M, Krischer J, Tamura R et al (2019) Randomized trial of lisinopril versus carvedilol to prevent trastuzumab cardiotoxicity in patients with breast cancer. J Am Coll Cardiol 73:2859\u20132868","journal-title":"J Am Coll Cardiol"},{"key":"1636_CR51","doi-asserted-by":"crossref","first-page":"3207","DOI":"10.1172\/JCI86249","volume":"126","author":"C Guignabert","year":"2016","unstructured":"Guignabert C, Phan C, Seferian A et al (2016) Dasatinib induces lung vascular toxicity and predisposes to pulmonary hypertension. J Clin Invest 126:3207\u20133218","journal-title":"J Clin Invest"},{"key":"1636_CR52","doi-asserted-by":"crossref","first-page":"4048","DOI":"10.1158\/1078-0432.CCR-15-0215","volume":"21","author":"NB Haas","year":"2015","unstructured":"Haas NB, Manola J, Ky B et al (2015) Effects of adjuvant sorafenib and sunitinib on cardiac function in renal cell carcinoma patients without overt metastases: results from ASSURE, ECOG 2805. Clin Cancer Res 21:4048\u20134054","journal-title":"Clin Cancer Res"},{"key":"1636_CR53","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1161\/CIRCULATIONAHA.115.016686","volume":"133","author":"N Haddy","year":"2016","unstructured":"Haddy N, Diallo S, El-Fayech C et al (2016) Cardiac diseases following childhood cancer treatment. Circulation 133:31\u201338","journal-title":"Circulation"},{"key":"1636_CR54","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1055\/s-0039-1688787","volume":"119","author":"A Hamadi","year":"2019","unstructured":"Hamadi A, Grigg AP, Dobie G et al (2019) Ponatinib tyrosine kinase inhibitor induces a thromboinflammatory response. Thromb Haemost 119:1112\u20131123","journal-title":"Thromb Haemost"},{"key":"1636_CR55","doi-asserted-by":"crossref","first-page":"S4296","DOI":"10.21037\/jtd.2018.09.87","volume":"10","author":"MB Heckmann","year":"2018","unstructured":"Heckmann MB, Doroudgar S, Katus HA et al (2018) Cardiovascular adverse events in multiple myeloma patients. J Thorac Dis 10:S4296\u2013S4305","journal-title":"J Thorac Dis"},{"key":"1636_CR56","doi-asserted-by":"crossref","first-page":"1864","DOI":"10.1200\/JCO.2004.06.033","volume":"22","author":"O Hequet","year":"2004","unstructured":"Hequet O, Le QH, Moullet I et al (2004) Subclinical late cardiomyopathy after doxorubicin therapy for lymphoma in adults. J Clin Oncol 22:1864\u20131871","journal-title":"J Clin Oncol"},{"key":"1636_CR57","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1093\/eurheartj\/ehz046","volume":"40","author":"D Hilfiker-Kleiner","year":"2019","unstructured":"Hilfiker-Kleiner D, Ardehali H, Fischmeister R et al (2019) Late onset heart failure after childhood chemotherapy. Eur Heart J 40:798\u2013800","journal-title":"Eur Heart J"},{"key":"1636_CR58","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1093\/jnci\/djk064","volume":"99","author":"MJ Hooning","year":"2007","unstructured":"Hooning MJ, Botma A, Aleman BMP et al (2007) Long-term risk of cardiovascular disease in 10-year survivors of breast cancer. J Natl Cancer Inst 99:365\u2013375","journal-title":"J Natl Cancer Inst"},{"key":"1636_CR59","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1093\/cvr\/cvz026","volume":"115","author":"JR Hu","year":"2019","unstructured":"Hu JR, Florido R, Lipson EJ et al (2019) Cardiovascular toxicities associated with immune checkpoint inhibitors. Cardiovasc Res 115:854\u2013868","journal-title":"Cardiovasc Res"},{"key":"1636_CR60","doi-asserted-by":"crossref","first-page":"2319","DOI":"10.1016\/j.jacc.2013.01.090","volume":"61","author":"C Jaworski","year":"2013","unstructured":"Jaworski C, Mariani JA, Wheeler G et al (2013) Cardiac complications of thoracic irradiation. J Am Coll Cardiol 61:2319\u20132328","journal-title":"J Am Coll Cardiol"},{"key":"1636_CR61","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1007\/s10549-019-05303-y","volume":"177","author":"G Jerusalem","year":"2019","unstructured":"Jerusalem G, Lancellotti P, Kim SB (2019) HER2+ breast cancer treatment and cardiotoxicity: monitoring and management. Breast Cancer Res Treat 177:237\u2013250","journal-title":"Breast Cancer Res Treat"},{"key":"1636_CR62","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1016\/j.hrthm.2019.04.008","volume":"16","author":"L Jiang","year":"2019","unstructured":"Jiang L, Li L, Ruan Y et al (2019) Ibrutinib promotes atrial fibrillation by inducing structural remodeling and calcium dysregulation in the atrium. Heart Rhythm 16:1374\u20131382","journal-title":"Heart Rhythm"},{"key":"1636_CR63","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1186\/s40425-017-0258-x","volume":"5","author":"S John","year":"2017","unstructured":"John S, Antonia SJ, Rose TA et al (2017) Progressive hypoventilation due to mixed CD8(+) and CD4(+) lymphocytic polymyositis following tremelimumab\u2013durvalumab treatment. J Immunother Cancer 5:54","journal-title":"J Immunother Cancer"},{"key":"1636_CR64","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1056\/NEJMoa1609214","volume":"375","author":"DB Johnson","year":"2016","unstructured":"Johnson DB, Balko JM, Compton ML et al (2016) Fulminant myocarditis with combination immune checkpoint blockade. N Engl J Med 375:1749\u20131755","journal-title":"N Engl J Med"},{"key":"1636_CR65","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1038\/bjc.2015.82","volume":"112","author":"JS Kloth","year":"2015","unstructured":"Kloth JS, Pagani A, Verboom MC et al (2015) Incidence and relevance of QTc-interval prolongation caused by tyrosine kinase inhibitors. Br J Cancer 112:1011\u20131016","journal-title":"Br J Cancer"},{"key":"1636_CR66","doi-asserted-by":"crossref","first-page":"2079","DOI":"10.1056\/NEJMc053530","volume":"354","author":"R Knight","year":"2006","unstructured":"Knight R, Delap RJ, Zeldis JB (2006) Lenalidomide and venous thrombosis in multiple myeloma. N Engl J Med 354:2079\u20132080","journal-title":"N Engl J Med"},{"key":"1636_CR67","doi-asserted-by":"crossref","first-page":"e314","DOI":"10.3747\/co.26.4823","volume":"26","author":"P Kosalka","year":"2019","unstructured":"Kosalka P, Johnson C, Turek M et al (2019) Effect of obesity, dyslipidemia, and diabetes on trastuzumab-related cardiotoxicity in breast cancer. Curr Oncol 26:e314\u2013e321","journal-title":"Curr Oncol"},{"key":"1636_CR68","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1093\/ehjci\/jet123","volume":"14","author":"P Lancellotti","year":"2013","unstructured":"Lancellotti P, Nkomo VT, Badano LP et al (2013) Expert consensus for multi-modality imaging evaluation of cardiovascular complications of radiotherapy in adults: a report from the European Association of Cardiovascular Imaging and the American Society of Echocardiography. Eur Heart J Cardiovasc Imaging 14:721\u2013740","journal-title":"Eur Heart J Cardiovasc Imaging"},{"key":"1636_CR69","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1093\/eurheartj\/ehy453","volume":"40","author":"P Lancellotti","year":"2019","unstructured":"Lancellotti P, Suter TM, Lopez-Fernandez T et al (2019) Cardio-oncology services: rationale, organization, and implementation. Eur Heart J 40:1756\u20131763","journal-title":"Eur Heart J"},{"key":"1636_CR70","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1055\/a-0754-2362","volume":"230","author":"T Langer","year":"2018","unstructured":"Langer T, Grabow D, Kaatsch P et al (2018) Long-term follow-up in childhood cancer survivors\u2014position paper 2018 of the working group \"long-term follow-up\" of the Society of Pediatric Oncology and Hematology (GPOH) on long-term surveillance, long-term follow-up and late effect evaluation in pediatric oncology patients. Klin Padiatr 230:291\u2013298","journal-title":"Klin Padiatr"},{"key":"1636_CR71","doi-asserted-by":"crossref","first-page":"4541","DOI":"10.1182\/blood.V124.21.4541.4541","volume":"124","author":"RA Larson","year":"2014","unstructured":"Larson RA, Kim D-W, Issaragrilsil S et al (2014) Efficacy and safety of nilotinib (NIL) vs imatinib (IM) in patients (pts) with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP): long-term follow-up (f\/u) of ENESTnd. Blood 124:4541\u20134541","journal-title":"Blood"},{"key":"1636_CR72","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1182\/blood-2018-10-881557","volume":"133","author":"Y Latifi","year":"2019","unstructured":"Latifi Y, Moccetti F, Wu M et al (2019) Thrombotic microangiopathy as a cause of cardiovascular toxicity from the BCR-ABL1 tyrosine kinase inhibitor ponatinib. Blood 133:1597\u20131606","journal-title":"Blood"},{"key":"1636_CR73","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1007\/s11936-019-0737-0","volume":"21","author":"K Lee Chuy","year":"2019","unstructured":"Lee Chuy K, Nahhas O, Dominic P et al (2019) Cardiovascular complications associated with mediastinal radiation. Curr Treat Options Cardiovasc Med 21:31","journal-title":"Curr Treat Options Cardiovasc Med"},{"key":"1636_CR74","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1007\/s11936-018-0618-y","volume":"20","author":"DH Lee","year":"2018","unstructured":"Lee DH, Fradley MG (2018) Cardiovascular complications of multiple myeloma treatment: evaluation, management, and prevention. Curr Treat Options Cardiovasc Med 20:19","journal-title":"Curr Treat Options Cardiovasc Med"},{"key":"1636_CR75","doi-asserted-by":"crossref","first-page":"e0195577","DOI":"10.1371\/journal.pone.0195577","volume":"13","author":"HA Lee","year":"2018","unstructured":"Lee HA, Hyun SA, Byun B et al (2018) Electrophysiological mechanisms of vandetanib-induced cardiotoxicity: comparison of action potentials in rabbit Purkinje fibers and pluripotent stem cell-derived cardiomyocytes. PLoS ONE 13:e0195577","journal-title":"PLoS ONE"},{"key":"1636_CR76","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1007\/s00018-013-1516-9","volume":"71","author":"LH Lehmann","year":"2014","unstructured":"Lehmann LH, Worst BC, Stanmore DA et al (2014) Histone deacetylase signaling in cardioprotection. Cell Mol Life Sci 71:1673\u20131690","journal-title":"Cell Mol Life Sci"},{"key":"1636_CR77","doi-asserted-by":"crossref","first-page":"3657","DOI":"10.1200\/JCO.2012.45.2938","volume":"30","author":"DJ Lenihan","year":"2012","unstructured":"Lenihan DJ, Cardinale DM (2012) Late cardiac effects of cancer treatment. J Clin Oncol 30:3657\u20133664","journal-title":"J Clin Oncol"},{"key":"1636_CR78","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1016\/j.cardfail.2016.03.012","volume":"22","author":"DJ Lenihan","year":"2016","unstructured":"Lenihan DJ, Hartlage G, Decara J et al (2016) Cardio-oncology training: a proposal from the international cardioncology society and Canadian cardiac oncology network for a new multidisciplinary specialty. J Card Fail 22:465\u2013471","journal-title":"J Card Fail"},{"key":"1636_CR79","doi-asserted-by":"crossref","first-page":"354ra114","DOI":"10.1126\/scitranslmed.aaf5309","volume":"8","author":"JT Leonard","year":"2016","unstructured":"Leonard JT, Rowley JS, Eide CA et al (2016) Targeting BCL-2 and ABL\/LYN in Philadelphia chromosome-positive acute lymphoblastic leukemia. Sci Transl Med 8:354ra114","journal-title":"Sci Transl Med"},{"key":"1636_CR80","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1378\/chest.09-1584","volume":"137","author":"GY Lip","year":"2010","unstructured":"Lip GY, Nieuwlaat R, Pisters R et al (2010) Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation. Chest 137:263\u2013272","journal-title":"Chest"},{"key":"1636_CR81","doi-asserted-by":"crossref","first-page":"1927","DOI":"10.1161\/CIR.0b013e3182a88099","volume":"128","author":"SE Lipshultz","year":"2013","unstructured":"Lipshultz SE, Adams MJ, Colan SD et al (2013) Long-term cardiovascular toxicity in children, adolescents, and young adults who receive cancer therapy: pathophysiology, course, monitoring, management, prevention, and research directions: a scientific statement from the American Heart Association. Circulation 128:1927\u20131995","journal-title":"Circulation"},{"key":"1636_CR82","doi-asserted-by":"crossref","first-page":"e008777","DOI":"10.1161\/CIRCIMAGING.118.008777","volume":"12","author":"MB Lustberg","year":"2019","unstructured":"Lustberg MB, Reinbolt R, Addison D et al (2019) Early detection of anthracycline-induced cardiotoxicity in breast cancer survivors with T2 cardiac magnetic resonance. Circ Cardiovasc Imaging 12:e008777","journal-title":"Circ Cardiovasc Imaging"},{"key":"1636_CR83","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1007\/s10549-019-05191-2","volume":"175","author":"F Lynce","year":"2019","unstructured":"Lynce F, Barac A, Geng X et al (2019) Prospective evaluation of the cardiac safety of HER2-targeted therapies in patients with HER2-positive breast cancer and compromised heart function: the SAFE-HEaRt study. Breast Cancer Res Treat 175:595\u2013603","journal-title":"Breast Cancer Res Treat"},{"key":"1636_CR84","doi-asserted-by":"crossref","first-page":"e447","DOI":"10.1016\/S1470-2045(18)30457-1","volume":"19","author":"AR Lyon","year":"2018","unstructured":"Lyon AR, Yousaf N, Battisti NML et al (2018) Immune checkpoint inhibitors and cardiovascular toxicity. Lancet Oncol 19:e447\u2013e458","journal-title":"Lancet Oncol"},{"key":"1636_CR85","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1016\/j.jacc.2018.02.037","volume":"71","author":"SS Mahmood","year":"2018","unstructured":"Mahmood SS, Fradley MG, Cohen JV et al (2018) Myocarditis in patients treated with immune checkpoint inhibitors. J Am Coll Cardiol 71:1755\u20131764","journal-title":"J Am Coll Cardiol"},{"key":"1636_CR86","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1200\/JCO.2012.46.6854","volume":"31","author":"MS Mccabe","year":"2013","unstructured":"Mccabe MS, Bhatia S, Oeffinger KC et al (2013) American Society of Clinical Oncology statement: achieving high-quality cancer survivorship care. J Clin Oncol 31:631\u2013640","journal-title":"J Clin Oncol"},{"key":"1636_CR87","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.radonc.2017.11.014","volume":"127","author":"PY Mclaughlin","year":"2018","unstructured":"Mclaughlin PY, Kong W, De Metz C et al (2018) Do radiation oncology outreach clinics affect the use of radiotherapy? Radiother Oncol 127:143\u2013149","journal-title":"Radiother Oncol"},{"key":"1636_CR88","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.blre.2018.01.004","volume":"32","author":"BC Medeiros","year":"2018","unstructured":"Medeiros BC, Possick J, Fradley M (2018) Cardiovascular, pulmonary, and metabolic toxicities complicating tyrosine kinase inhibitor therapy in chronic myeloid leukemia: strategies for monitoring, detecting, and managing. Blood Rev 32:289\u2013299","journal-title":"Blood Rev"},{"key":"1636_CR89","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1177\/2045125317721662","volume":"7","author":"AD Meid","year":"2017","unstructured":"Meid AD, Bighelli I, Machler S et al (2017) Combinations of QTc-prolonging drugs: towards disentangling pharmacokinetic and pharmacodynamic effects in their potentially additive nature. Ther Adv Psychopharmacol 7:251\u2013264","journal-title":"Ther Adv Psychopharmacol"},{"key":"1636_CR90","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1093\/cvr\/cvz035","volume":"115","author":"WC Meijers","year":"2019","unstructured":"Meijers WC, De Boer RA (2019) Common risk factors for heart failure and cancer. Cardiovasc Res 115:844\u2013853","journal-title":"Cardiovasc Res"},{"issue":"2","key":"1636_CR91","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1002\/ejhf.1631","volume":"22","author":"L Michel","year":"2020","unstructured":"Michel L, Mincu RI, Mahabadi AA et al (2020) Troponins and brain natriuretic peptides for the prediction of cardiotoxicity in cancer patients: a meta-analysis. Eur J Heart Fail 22(2):350\u2013361. https:\/\/doi.org\/10.1002\/ejhf.1631","journal-title":"Eur J Heart Fail"},{"key":"1636_CR92","doi-asserted-by":"crossref","first-page":"S4282","DOI":"10.21037\/jtd.2018.08.15","volume":"10","author":"L Michel","year":"2018","unstructured":"Michel L, Rassaf T, Totzeck M (2018) Biomarkers for the detection of apparent and subclinical cancer therapy-related cardiotoxicity. J Thorac Dis 10:S4282\u2013S4295","journal-title":"J Thorac Dis"},{"key":"1636_CR93","doi-asserted-by":"crossref","first-page":"e198890","DOI":"10.1001\/jamanetworkopen.2019.8890","volume":"2","author":"RI Mincu","year":"2019","unstructured":"Mincu RI, Mahabadi AA, Michel L et al (2019) Cardiovascular adverse events associated with BRAF and MEK inhibitors: a systematic review and meta-analysis. JAMA Netw Open 2:e198890","journal-title":"JAMA Netw Open"},{"key":"1636_CR94","doi-asserted-by":"crossref","first-page":"3173","DOI":"10.1200\/JCO.2001.19.13.3173","volume":"19","author":"TR Moller","year":"2001","unstructured":"Moller TR, Garwicz S, Barlow L et al (2001) Decreasing late mortality among five-year survivors of cancer in childhood and adolescence: a population-based study in the Nordic countries. J Clin Oncol 19:3173\u20133181","journal-title":"J Clin Oncol"},{"key":"1636_CR95","doi-asserted-by":"crossref","first-page":"iv52","DOI":"10.1093\/annonc\/mdx096","volume":"28","author":"P Moreau","year":"2017","unstructured":"Moreau P, San Miguel J, Sonneveld P et al (2017) Multiple myeloma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 28:iv52\u2013iv61","journal-title":"Ann Oncol"},{"key":"1636_CR96","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1056\/NEJMc1610003","volume":"376","author":"JJ Moslehi","year":"2017","unstructured":"Moslehi JJ, Johnson DB, Sosman JA (2017) Myocarditis with immune checkpoint blockade. N Engl J Med 376:292","journal-title":"N Engl J Med"},{"key":"1636_CR97","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1016\/S0140-6736(18)30533-6","volume":"391","author":"JJ Moslehi","year":"2018","unstructured":"Moslehi JJ, Salem JE, Sosman JA et al (2018) Increased reporting of fatal immune checkpoint inhibitor-associated myocarditis. Lancet 391:933","journal-title":"Lancet"},{"key":"1636_CR98","doi-asserted-by":"crossref","first-page":"b4606","DOI":"10.1136\/bmj.b4606","volume":"339","author":"DA Mulrooney","year":"2009","unstructured":"Mulrooney DA, Yeazel MW, Kawashima T et al (2009) Cardiac outcomes in a cohort of adult survivors of childhood and adolescent cancer: retrospective analysis of the Childhood Cancer Survivor Study cohort. BMJ 339:b4606","journal-title":"BMJ"},{"key":"1636_CR99","doi-asserted-by":"crossref","first-page":"H466","DOI":"10.1152\/ajpheart.00720.2015","volume":"310","author":"KT Murphy","year":"2016","unstructured":"Murphy KT (2016) The pathogenesis and treatment of cardiac atrophy in cancer cachexia. Am J Physiol Heart Circ Physiol 310:H466\u2013477","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"1636_CR100","doi-asserted-by":"crossref","first-page":"3601","DOI":"10.1158\/1078-0432.CCR-16-2869","volume":"23","author":"V Narayan","year":"2017","unstructured":"Narayan V, Keefe S, Haas N et al (2017) Prospective evaluation of sunitinib-induced cardiotoxicity in patients with metastatic renal cell carcinoma. Clin Cancer Res 23:3601\u20133609","journal-title":"Clin Cancer Res"},{"key":"1636_CR101","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1126\/science.1241908","volume":"342","author":"ER Nelson","year":"2013","unstructured":"Nelson ER, Wardell SE, Jasper JS et al (2013) 27-Hydroxycholesterol links hypercholesterolemia and breast cancer pathophysiology. Science 342:1094\u20131098","journal-title":"Science"},{"key":"1636_CR102","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.echo.2018.09.019","volume":"32","author":"LF Nhola","year":"2019","unstructured":"Nhola LF, Abdelmoneim SS, Villarraga HR et al (2019) Echocardiographic assessment for the detection of cardiotoxicity due to vascular endothelial growth factor inhibitor therapy in metastatic renal cell and colorectal cancers. J Am Soc Echocardiogr 32:267\u2013276","journal-title":"J Am Soc Echocardiogr"},{"key":"1636_CR103","doi-asserted-by":"crossref","first-page":"2658","DOI":"10.2353\/ajpath.2010.090690","volume":"176","author":"D Nowis","year":"2010","unstructured":"Nowis D, Maczewski M, Mackiewicz U et al (2010) Cardiotoxicity of the anticancer therapeutic agent bortezomib. Am J Pathol 176:2658\u20132668","journal-title":"Am J Pathol"},{"key":"1636_CR104","doi-asserted-by":"crossref","first-page":"e008637","DOI":"10.1161\/JAHA.118.008637","volume":"7","author":"S Nowsheen","year":"2018","unstructured":"Nowsheen S, Aziz K, Park JY et al (2018) Trastuzumab in female breast cancer patients with reduced left ventricular ejection fraction. J Am Heart Assoc 7:e008637","journal-title":"J Am Heart Assoc"},{"key":"1636_CR105","doi-asserted-by":"crossref","first-page":"1572","DOI":"10.1056\/NEJMsa060185","volume":"355","author":"KC Oeffinger","year":"2006","unstructured":"Oeffinger KC, Mertens AC, Sklar CA et al (2006) Chronic health conditions in adult survivors of childhood cancer. N Engl J Med 355:1572\u20131582","journal-title":"N Engl J Med"},{"key":"1636_CR106","doi-asserted-by":"crossref","first-page":"413","DOI":"10.2217\/FCA.15.43","volume":"11","author":"TM Okwuosa","year":"2015","unstructured":"Okwuosa TM, Akhter N, Williams KA et al (2015) Building a cardio-oncology program in a small- to medium-sized, nonprimary cancer center, academic hospital in the USA: challenges and pitfalls. Future Cardiol 11:413\u2013420","journal-title":"Future Cardiol"},{"key":"1636_CR107","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1002\/cam4.622","volume":"5","author":"SH Ou","year":"2016","unstructured":"Ou SH, Tang Y, Polli A et al (2016) Factors associated with sinus bradycardia during crizotinib treatment: a retrospective analysis of two large-scale multinational trials (PROFILE 1005 and 1007). Cancer Med 5:617\u2013622","journal-title":"Cancer Med"},{"key":"1636_CR108","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1016\/j.cjca.2016.04.014","volume":"32","author":"S Parent","year":"2016","unstructured":"Parent S, Pituskin E, Paterson DI (2016) The cardio-oncology program: a multidisciplinary approach to the care of cancer patients with cardiovascular disease. Can J Cardiol 32:847\u2013851","journal-title":"Can J Cardiol"},{"key":"1636_CR109","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaccao.2019.09.008","author":"TJ Pfeffer","year":"2019","unstructured":"Pfeffer TJ, Schlothauer S, Pietzsch S et al (2019) Increased cancer prevalence in peripartum cardiomyopathy. JACC CardioOncol. https:\/\/doi.org\/10.1016\/j.jaccao.2019.09.008","journal-title":"JACC CardioOncol"},{"key":"1636_CR110","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1016\/j.echo.2014.07.012","volume":"27","author":"JC Plana","year":"2014","unstructured":"Plana JC, Galderisi M, Barac A et al (2014) Expert consensus for multimodality imaging evaluation of adult patients during and after cancer therapy: a report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J Am Soc Echocardiogr 27:911\u2013939","journal-title":"J Am Soc Echocardiogr"},{"key":"1636_CR111","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1093\/eurheartj\/ehw128","volume":"37","author":"P Ponikowski","year":"2016","unstructured":"Ponikowski P, Voors AA, Anker SD et al (2016) 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: the task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J 37:2129\u20132200","journal-title":"Eur Heart J"},{"key":"1636_CR112","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1016\/j.bbmt.2009.06.001","volume":"15","author":"MH Qazilbash","year":"2009","unstructured":"Qazilbash MH, Amjad AI, Qureshi S et al (2009) Outcome of allogeneic hematopoietic stem cell transplantation in patients with low left ventricular ejection fraction. Biol Blood Marrow Transplant 15:1265\u20131270","journal-title":"Biol Blood Marrow Transplant"},{"key":"1636_CR113","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1016\/j.ajpath.2014.10.021","volume":"185","author":"B Ranchoux","year":"2015","unstructured":"Ranchoux B, Gunther S, Quarck R et al (2015) Chemotherapy-induced pulmonary hypertension: role of alkylating agents. Am J Pathol 185:356\u2013371","journal-title":"Am J Pathol"},{"key":"1636_CR114","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1038\/leu.2014.342","volume":"29","author":"D Rea","year":"2015","unstructured":"Rea D, Mirault T, Raffoux E et al (2015) Usefulness of the 2012 European CVD risk assessment model to identify patients at high risk of cardiovascular events during nilotinib therapy in chronic myeloid leukemia. Leukemia 29:1206\u20131209","journal-title":"Leukemia"},{"key":"1636_CR115","doi-asserted-by":"crossref","first-page":"E15","DOI":"10.1002\/ajh.24599","volume":"92","author":"JC Reneau","year":"2017","unstructured":"Reneau JC, Asante D, Van Houten H et al (2017) Cardiotoxicity risk with bortezomib versus lenalidomide for treatment of multiple myeloma: a propensity matched study of 1790 patients. Am J Hematol 92:E15\u2013E17","journal-title":"Am J Hematol"},{"key":"1636_CR116","doi-asserted-by":"publisher","DOI":"10.1093\/cvr\/cvz300","author":"M Ricke-Hoch","year":"2019","unstructured":"Ricke-Hoch M, Hoes MF, Pfeffer TJ et al (2019) In peripartum cardiomyopathy Plasminogen Activator Inhibitor-1 is a potential new biomarker with controversial roles. Cardiovasc Res. https:\/\/doi.org\/10.1093\/cvr\/cvz300","journal-title":"Cardiovasc Res"},{"key":"1636_CR117","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1007\/s00277-017-3004-z","volume":"96","author":"R Rodriguez-Veiga","year":"2017","unstructured":"Rodriguez-Veiga R, Igual B, Montesinos P et al (2017) Assessment of late cardiomyopathy by magnetic resonance imaging in patients with acute promyelocytic leukaemia treated with all-trans retinoic acid and idarubicin. Ann Hematol 96:1077\u20131084","journal-title":"Ann Hematol"},{"key":"1636_CR118","doi-asserted-by":"crossref","first-page":"e384","DOI":"10.1038\/bcj.2015.112","volume":"6","author":"A Rosenthal","year":"2016","unstructured":"Rosenthal A, Luthi J, Belohlavek M et al (2016) Carfilzomib and the cardiorenal system in myeloma: an endothelial effect? Blood Cancer J 6:e384","journal-title":"Blood Cancer J"},{"key":"1636_CR119","doi-asserted-by":"crossref","first-page":"2377","DOI":"10.1056\/NEJMc1901677","volume":"380","author":"JE Salem","year":"2019","unstructured":"Salem JE, Allenbach Y, Vozy A et al (2019) Abatacept for severe immune checkpoint inhibitor-associated myocarditis. N Engl J Med 380:2377\u20132379","journal-title":"N Engl J Med"},{"key":"1636_CR120","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1016\/S1470-2045(18)30608-9","volume":"19","author":"JE Salem","year":"2018","unstructured":"Salem JE, Manouchehri A, Moey M et al (2018) Cardiovascular toxicities associated with immune checkpoint inhibitors: an observational, retrospective, pharmacovigilance study. Lancet Oncol 19:1579\u20131589","journal-title":"Lancet Oncol"},{"key":"1636_CR121","doi-asserted-by":"crossref","first-page":"175883591878014","DOI":"10.1177\/1758835918780140","volume":"10","author":"JD Sara","year":"2018","unstructured":"Sara JD, Kaur J, Khodadadi R et al (2018) 5-fluorouracil and cardiotoxicity: a review. Ther Adv Med Oncol 10:1758835918780140","journal-title":"Ther Adv Med Oncol"},{"key":"1636_CR122","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1038\/s41375-018-0315-6","volume":"33","author":"M Scherr","year":"2019","unstructured":"Scherr M, Kirchhoff H, Battmer K et al (2019) Optimized induction of mitochondrial apoptosis for chemotherapy-free treatment of BCR-ABL+acute lymphoblastic leukemia. Leukemia 33:1313\u20131323","journal-title":"Leukemia"},{"key":"1636_CR123","doi-asserted-by":"crossref","first-page":"3997","DOI":"10.1158\/1078-0432.CCR-05-2689","volume":"12","author":"MH Shah","year":"2006","unstructured":"Shah MH, Binkley P, Chan K et al (2006) Cardiotoxicity of histone deacetylase inhibitor depsipeptide in patients with metastatic neuroendocrine tumors. Clin Cancer Res 12:3997\u20134003","journal-title":"Clin Cancer Res"},{"key":"1636_CR124","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1002\/ajh.24174","volume":"90","author":"NP Shah","year":"2015","unstructured":"Shah NP, Wallis N, Farber HW et al (2015) Clinical features of pulmonary arterial hypertension in patients receiving dasatinib. Am J Hematol 90:1060\u20131064","journal-title":"Am J Hematol"},{"key":"1636_CR125","doi-asserted-by":"crossref","first-page":"1753","DOI":"10.3324\/haematol.2013.089334","volume":"98","author":"D Siegel","year":"2013","unstructured":"Siegel D, Martin T, Nooka A et al (2013) Integrated safety profile of single-agent carfilzomib: experience from 526 patients enrolled in 4 phase II clinical studies. Haematologica 98:1753\u20131761","journal-title":"Haematologica"},{"key":"1636_CR126","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1056\/NEJM200103153441101","volume":"344","author":"DJ Slamon","year":"2001","unstructured":"Slamon DJ, Leyland-Jones B, Shak S et al (2001) Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344:783\u2013792","journal-title":"N Engl J Med"},{"key":"1636_CR127","doi-asserted-by":"crossref","first-page":"4606","DOI":"10.1182\/blood-2007-06-096966","volume":"110","author":"ML Sorror","year":"2007","unstructured":"Sorror ML, Giralt S, Sandmaier BM et al (2007) Hematopoietic cell transplantation specific comorbidity index as an outcome predictor for patients with acute myeloid leukemia in first remission: combined FHCRC and MDACC experiences. Blood 110:4606\u20134613","journal-title":"Blood"},{"key":"1636_CR128","doi-asserted-by":"crossref","first-page":"2912","DOI":"10.1182\/blood-2005-05-2004","volume":"106","author":"ML Sorror","year":"2005","unstructured":"Sorror ML, Maris MB, Storb R et al (2005) Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT. Blood 106:2912\u20132919","journal-title":"Blood"},{"key":"1636_CR129","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.ahj.2011.10.018","volume":"163","author":"RM Steingart","year":"2012","unstructured":"Steingart RM, Bakris GL, Chen HX et al (2012) Management of cardiac toxicity in patients receiving vascular endothelial growth factor signaling pathway inhibitors. Am Heart J 163:156\u2013163","journal-title":"Am Heart J"},{"key":"1636_CR130","doi-asserted-by":"crossref","first-page":"1672","DOI":"10.1001\/jama.1991.03470120074036","volume":"266","author":"LJ Steinherz","year":"1991","unstructured":"Steinherz LJ, Steinherz PG, Tan CT et al (1991) Cardiac toxicity 4 to 20 years after completing anthracycline therapy. JAMA 266:1672\u20131677","journal-title":"JAMA"},{"key":"1636_CR131","doi-asserted-by":"crossref","first-page":"2121","DOI":"10.2217\/fon.15.123","volume":"11","author":"AK Stewart","year":"2015","unstructured":"Stewart AK (2015) Carfilzomib for the treatment of patients with relapsed and\/or refractory multiple myeloma. Future Oncol 11:2121\u20132136","journal-title":"Future Oncol"},{"key":"1636_CR132","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1161\/HYPERTENSIONAHA.111.189258","volume":"59","author":"T Stocks","year":"2012","unstructured":"Stocks T, Van Hemelrijck M, Manjer J et al (2012) Blood pressure and risk of cancer incidence and mortality in the Metabolic Syndrome and Cancer Project. Hypertension 59:802\u2013810","journal-title":"Hypertension"},{"issue":"10","key":"1636_CR133","doi-asserted-by":"publisher","first-page":"e006635","DOI":"10.1161\/JAHA.117.006635","volume":"6","author":"TJ Stuhlmiller","year":"2017","unstructured":"Stuhlmiller TJ, Zawistowski JS, Chen X et al (2017) Kinome and transcriptome profiling reveal broad and distinct activities of erlotinib, sunitinib, and sorafenib in the mouse heart and suggest cardiotoxicity from combined signal transducer and activator of transcription and epidermal growth factor receptor inhibition. J Am Heart Assoc 6(10):e006635. https:\/\/doi.org\/10.1161\/JAHA.117.006635","journal-title":"J Am Heart Assoc"},{"key":"1636_CR134","doi-asserted-by":"crossref","first-page":"2751","DOI":"10.3390\/ph3092751","volume":"3","author":"S Subramanian","year":"2010","unstructured":"Subramanian S, Bates SE, Wright JJ et al (2010) Clinical toxicities of histone deacetylase inhibitors. Pharmaceuticals 3:2751\u20132767","journal-title":"Pharmaceuticals"},{"key":"1636_CR135","doi-asserted-by":"crossref","first-page":"e6394","DOI":"10.1097\/MD.0000000000006394","volume":"96","author":"H Sun","year":"2017","unstructured":"Sun H, Li T, Zhuang R et al (2017) Do renin-angiotensin system inhibitors influence the recurrence, metastasis, and survival in cancer patients?: Evidence from a meta-analysis including 55 studies. Medicine (Baltimore) 96:e6394","journal-title":"Medicine (Baltimore)"},{"key":"1636_CR136","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1212\/WNL.0000000000004359","volume":"89","author":"S Suzuki","year":"2017","unstructured":"Suzuki S, Ishikawa N, Konoeda F et al (2017) Nivolumab-related myasthenia gravis with myositis and myocarditis in Japan. Neurology 89:1127\u20131134","journal-title":"Neurology"},{"key":"1636_CR137","doi-asserted-by":"crossref","first-page":"2869","DOI":"10.1002\/cncr.11407","volume":"97","author":"SM Swain","year":"2003","unstructured":"Swain SM, Whaley FS, Ewer MS (2003) Congestive heart failure in patients treated with doxorubicin: a retrospective analysis of three trials. Cancer 97:2869\u20132879","journal-title":"Cancer"},{"key":"1636_CR138","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.1200\/JCO.2016.72.0722","volume":"35","author":"C Taylor","year":"2017","unstructured":"Taylor C, Correa C, Duane FK et al (2017) Estimating the risks of breast cancer radiotherapy: evidence from modern radiation doses to the lungs and heart and from previous randomized trials. J Clin Oncol 35:1641\u20131649","journal-title":"J Clin Oncol"},{"key":"1636_CR139","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.3324\/haematol.2014.117176","volume":"100","author":"E Terpos","year":"2015","unstructured":"Terpos E, Kleber M, Engelhardt M et al (2015) European Myeloma Network guidelines for the management of multiple myeloma-related complications. Haematologica 100:1254\u20131266","journal-title":"Haematologica"},{"key":"1636_CR140","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1007\/s00392-018-1202-x","volume":"107","author":"LM Tilemann","year":"2018","unstructured":"Tilemann LM, Heckmann MB, Katus HA et al (2018) Cardio-oncology: conflicting priorities of anticancer treatment and cardiovascular outcome. Clin Res Cardiol 107:271\u2013280","journal-title":"Clin Res Cardiol"},{"key":"1636_CR141","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.ijcard.2019.01.038","volume":"280","author":"M Totzeck","year":"2019","unstructured":"Totzeck M, Schuler M, Stuschke M et al (2019) Cardio-oncology\u2014strategies for management of cancer-therapy related cardiovascular disease. Int J Cardiol 280:163\u2013175","journal-title":"Int J Cardiol"},{"key":"1636_CR142","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1007\/s00246-010-9878-3","volume":"32","author":"BH Trachtenberg","year":"2011","unstructured":"Trachtenberg BH, Landy DC, Franco VI et al (2011) Anthracycline-associated cardiotoxicity in survivors of childhood cancer. Pediatr Cardiol 32:342\u2013353","journal-title":"Pediatr Cardiol"},{"key":"1636_CR143","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1001\/archinternmed.2010.233","volume":"170","author":"HJ Van Der Pal","year":"2010","unstructured":"Van Der Pal HJ, Van Dalen EC, Hauptmann M et al (2010) Cardiac function in 5-year survivors of childhood cancer: a long-term follow-up study. Arch Intern Med 170:1247\u20131255","journal-title":"Arch Intern Med"},{"key":"1636_CR144","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1001\/jamainternmed.2015.1180","volume":"175","author":"FA Van Nimwegen","year":"2015","unstructured":"Van Nimwegen FA, Schaapveld M, Janus CP et al (2015) Cardiovascular disease after Hodgkin lymphoma treatment: 40-year disease risk. JAMA Intern Med 175:1007\u20131017","journal-title":"JAMA Intern Med"},{"issue":"1","key":"1636_CR145","doi-asserted-by":"publisher","first-page":"1700217","DOI":"10.1183\/13993003.00217-2017","volume":"50","author":"J Weatherald","year":"2017","unstructured":"Weatherald J, Chaumais MC, Savale L et al (2017) Long-term outcomes of dasatinib-induced pulmonary arterial hypertension: a population-based study. Eur Respir J 50(1):1700217. https:\/\/doi.org\/10.1183\/13993003.00217-2017","journal-title":"Eur Respir J"},{"key":"1636_CR146","doi-asserted-by":"crossref","first-page":"3896","DOI":"10.1093\/eurheartj\/ehy167","volume":"39","author":"J Weberpals","year":"2018","unstructured":"Weberpals J, Jansen L, Muller OJ et al (2018) Long-term heart-specific mortality among 347 476 breast cancer patients treated with radiotherapy or chemotherapy: a registry-based cohort study. Eur Heart J 39:3896\u20133903","journal-title":"Eur Heart J"},{"key":"1636_CR147","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1182\/bloodadvances.2017009720","volume":"1","author":"TE Wiczer","year":"2017","unstructured":"Wiczer TE, Levine LB, Brumbaugh J et al (2017) Cumulative incidence, risk factors, and management of atrial fibrillation in patients receiving ibrutinib. Blood Adv 1:1739\u20131748","journal-title":"Blood Adv"},{"key":"1636_CR148","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1007\/s00392-019-01417-x","volume":"108","author":"HJ Yoon","year":"2019","unstructured":"Yoon HJ, Kim KH, Kim HY et al (2019) Impacts of non-recovery of trastuzumab-induced cardiomyopathy on clinical outcomes in patients with breast cancer. Clin Res Cardiol 108:892\u2013900","journal-title":"Clin Res Cardiol"},{"key":"1636_CR149","doi-asserted-by":"crossref","first-page":"2768","DOI":"10.1093\/eurheartj\/ehw211","volume":"37","author":"JL Zamorano","year":"2016","unstructured":"Zamorano JL, Lancellotti P, Rodriguez Munoz D et al (2016) 2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines: The Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC). Eur Heart J 37:2768\u20132801","journal-title":"Eur Heart J"},{"key":"1636_CR150","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s40959-017-0020-z","volume":"3","author":"Z Zhang","year":"2017","unstructured":"Zhang Z, Huang TQ, Nepliouev I et al (2017) Crizotinib inhibits hyperpolarization-activated cyclic nucleotide-gated channel 4 activity. Cardiooncology 3:1. https:\/\/doi.org\/10.1186\/s40959-017-0020-z","journal-title":"Cardiooncology"}],"container-title":["Clinical Research in Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00392-020-01636-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00392-020-01636-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00392-020-01636-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,12]],"date-time":"2021-05-12T23:29:23Z","timestamp":1620862163000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00392-020-01636-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5,13]]},"references-count":150,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2020,10]]}},"alternative-id":["1636"],"URL":"https:\/\/doi.org\/10.1007\/s00392-020-01636-7","relation":{},"ISSN":["1861-0684","1861-0692"],"issn-type":[{"value":"1861-0684","type":"print"},{"value":"1861-0692","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,5,13]]},"assertion":[{"value":"12 March 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 March 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 May 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}